Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(2): 170–172. doi: 10.48095/ccgh2021170.

Teduglutide, a glucagon-like peptide-2 analogue (REVESTIVE), in the treatment of short bowel syndrome with dependence on home parenteral nutrition

František Novák1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Jeppesen PB, Pertkiewicz M, Messing B et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143(6): 1473–1481. doi: 10.1053/j.gastro.2012.09.007.
2. Schwartz LK, O’Keefe SJD, Fujioka K et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol 2016; 7(2): e142. doi: 10.1038/ctg.2015.69.
3. Jeppesen PB, Gilroy R, Pertkiewicz M et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fl uid requirements in patients with short bowel syndrome. Gut 2011; 60: 902–914. doi: 10.1136/gut.2010.218271.
4. O’Keefe SJD, Jeppesen PB, Gilroy R et al. Safety and effi cacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol 2013: 11: 815–823. doi: 10.1016/j.cgh.2012.12. 029.
5. Společné stanovisko VZP ČR a SKVIMP ČLS JEP. 2020 [online]. Dostupné z: https://media. vzpstatic.cz/media/Default/dokumenty/spolecna-stanoviska/2020_06_10_spolecne-stanovisko_lp-revestive.pdf.
6. Wohl P, Šenkyřík M, Těšínský P et al. Konsenzus odborníků v léčbě SBS. 2019 [online]. Dostupné na: http://www.skvimp.cz/soubory/Advisory-Board-Revestive-Consensus-Praha-14.10.2019.pdf.

Credited self-teaching test